David H. Vesole

18.6k citations

210 papers · 10.3k indexed · 4 hit papers · h-index 43

Impact in

Hematology top 0.05%
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
Oncology top 0.5%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology

Papers in

Hematology 171
- Multiple Myeloma Research and Treatments 149
- Hematopoietic Stem Cell Transplantation 40
Genetics 32
- Chronic Lymphocytic Leukemia Research 25

Co-authors: Sundar Jagannath Bart Barlogie Guido Tricot David S. Siegel Morie A. Gertz Philip R. Greipp Joan Bladé Sergio Giralt
Journals: Blood (78 papers)Journal of Clinical Oncology (21 papers)Biology of Blood and Marrow Transplantation (17 papers)Bone Marrow Transplantation (11 papers)British Journal of Haematology (8 papers)
Partner nations: United States Canada Poland

In The Last Decade

David H. Vesole

199 papers receiving 10.1k citations

Hit Papers

align trajectories log scale

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial 2009 · 673 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 The Lancet Oncology
2007 New England Journal of Medicine
2004 Clinical Infectious Diseases
1998 British Journal of Haematology

Peers

Countries citing papers authored by David H. Vesole

Since Specialization

Citations

This map shows the geographic impact of David H. Vesole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Vesole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Vesole more than expected).

Fields of papers citing papers by David H. Vesole

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Vesole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Vesole. The network helps show where David H. Vesole may publish in the future.

Co-authors

The 25 scholars most cited alongside David H. Vesole, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David H. Vesole Line = papers co-authored together David H. Vesole links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Impact of Extramedullary Disease on Survival Outcomes in Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel and Idecabtagene Vicleucel: A Comparative Analysis Transplantation and Cellular Therapy ·Behzad Amoozgar, Ayrton Bangolo, Pooja Phull, David H. Vesole, David S. Siegel, Noa Biran, Michèle L. Donato, Christina Cho, Harsh Parmar	2025	1
2	Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM) Blood ·David H. Vesole, Thomas G Martin, Suzanne Trudel, Henning Schade, Samantha Shenoy, Noa Biran, Jeffrey L. Wolf, Jeffrey Matous, Pamela N. Münster, Savannah Berkeley, Jesús G. Berdeja	2024	1
3	MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma Blood ·H. Miles Prince, Nizar J. Bahlis, Paula Rodríguez‐Otero, Lionel Karlin, Luke P. Akard, Asya Varshavsky‐Yanovsky, Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin	2024	5
4	Comparison of Fludarabine/Cyclophosphamide Vs Bendamustine As Lymphodepleting Regimen for CAR-T: A Safety and Efficacy Analysis in Patients with Relapsed/ Refractory Multiple Myeloma Blood ·Sarvarinder Gill, Noa Biran, Pooja Phull, Sukhdeep Kaur, Hyung C. Suh, Christina Cho, Michèle L. Donato, Scott D. Rowley, David H. Vesole, David S. Siegel, Harsh Parmar	2023	1
5	Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation Transplantation and Cellular Therapy ·Sarah Makhani, Samir Oza, Ronit Reich‐Slotky, Pashna N. Munshi, Noa Biran, Michèle L. Donato, David S. Siegel, David H. Vesole, Suzan Naam, Scott D. Rowley	2022	1
6	A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial Transplantation and Cellular Therapy ·Qaiser Bashir, Taiga Nishihori, Marcelo C. Pasquini, Michael J. Martens, Juan Wu, Melissa Alsina, Claudio Anasetti, Claudio G. Brunstein, Peter Dawson, Yvonne A. Efebera, Cristina Gasparetto, Nancy L. Geller, Sergio Giralt, Aric C. Hall, John Koreth, Philip L. McCarthy, Emma Scott, Edward A. Stadtmauer, David H. Vesole, Parameswaran Hari	2022	5
7	Patient‐reported outcomes following autologous stem cell transplant for patients with multiple myeloma SHILAP Revista de lepidopterología ·Noa Biran, Wanting Zhai, Roxanne E. Jensen, Jeanne S. Mandelblatt, Susan Kumka, Rashmi Unawane, Kristi D. Graves, David H. Vesole, David S. Siegel, Arnold L. Potosky	2021	4
8	Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma Clinical Lymphoma Myeloma & Leukemia ·Joshua Richter, Larysa Sanchez, Noa Biran, C.K. Wang, Kathryn Tanenbaum, Victoria DeVincenzo, Brooke Grunman, David H. Vesole, David S. Siegel, Andrew L. Pecora, Stuart L. Goldberg	2020	15
9	A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma Blood ·Noa Biran, Tracy Andrews, Rena Feinman, David H. Vesole, Joshua R. Richter, Joshua Zenreich, Palka Anand, Laura McBride, Kristin Ivanovski, Robert Korngold, David S. Siegel	2017	8
10	Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies Biology of Blood and Marrow Transplantation ·Melissa Baker, Hongkun Wang, Scott D. Rowley, Ling Cai, Andrew L. Pecora, Alan P Skarbnik, David H. Vesole, Barbara Adler‐Brecher, Daniel Kim, Michèle L. Donato	2016	38
11	A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma Biology of Blood and Marrow Transplantation ·Noa Biran, Scott D. Rowley, David H. Vesole, Shijia Zhang, Michèle L. Donato, Joshua R. Richter, Alan P Skarbnik, Andrew L. Pecora, David S. Siegel	2016	11
12	Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplantation ·Binod Dhakal, David H. Vesole, Parameswaran Hari	2016	41
13	Multiple Myeloma in Pregnancy—A Review of the Literature and a Case Series Clinical Lymphoma Myeloma & Leukemia ·Artur Jurczyszyn, Magdalena Olszewska‐Szopa, Adam S. Vesole, David H. Vesole, David S. Siegel, Paul G. Richardson, Claudia E. Paba‐Prada, Natalie S. Callander, Hubert Huras, Aleksander B. Skotnicki	2015	8
14	Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma Anti-Cancer Drugs ·Jed Abraham Katzel, Annette Lee-Ma, David H. Vesole	2015	2
15	Donor CD3 Chimerism After Allogeneic Transplantation Predicts Probability Of Relapse For Patients Treated For Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Non-Hodkgin's Lymphoma (NHL) Blood ·Arpita P Gandhi, Michèle L. Donato, Themba Nyirenda, David H. Vesole, Andrew L. Pecora, Stuart L. Goldberg, André Goy, Tatyana Feldman, Anthony R. Mato, Pritish K. Bhattacharyya, Melissa Baker, Phyllis McKiernan, Brenda Díaz, Scott D. Rowley	2013	1
16	A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma Blood ·Andrzej Jakubowiak, Dominik Dytfeld, Kent A. Griffith, Daniel Lebovic, David H. Vesole, Sundar Jagannath, Ammar Al-Zoubi, Tara Anderson, Brian K. Nordgren, Kristen Detweiler‐Short, Keith Stockerl‐Goldstein, Asra Ahmed, Terri L. Jobkar, Diane E. Durecki, Kathryn McDonnell, M. Mietzel, Daniel R. Couriel, Mark Kaminski, Ravi Vij	2012	311
17	Enhancement of clonogenicity of human multiple myeloma by dendritic cells The Journal of Experimental Medicine ·Anjli Kukreja, Aisha Hutchinson, Kavita M. Dhodapkar, Amitabha Mazumder, David H. Vesole, Revathi Angitapalli, Sundar Jagannath, Madhav V. Dhodapkar	2006	103
18	Multiple myeloma: role of allogeneic transplantation. PubMed ·Sandeep R. Pandit, David H. Vesole	2002	2
19	Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony‐stimulating factor alone British Journal of Haematology ·K.R. Desikan, Guido Tricot, Nikhil C. Munshi, E. Anaissie, Dan Spoon, Athanasios Fassas, Amir A. Toor, Maurizio Zangari, Ashraf Badros, Christopher Morris, David H. Vesole, David S. Siegel, Sundar Jagannath, Bart Barlogie	2001	47
20	Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. Journal of Clinical Oncology ·K.R. Desikan, Bart Barlogie, Sundar Jagannath, David H. Vesole, David S. Siegel, Athanasios Fassas, Nikhil C. Munshi, Seema Singhal, J. L. Mehta, Sharon Tindle, J Nelson, D Bracy, S. Mattox, Guido Tricot	1998	135

About David H. Vesole

David H. Vesole is a scholar working on Hematology, Genetics, Oncology, Molecular Biology and Transplantation, having authored 210 papers that have together received 10.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (149 papers), Protein Degradation and Inhibitors (55 papers), Hematopoietic Stem Cell Transplantation (40 papers), Cancer Treatment and Pharmacology (30 papers), Chronic Lymphocytic Leukemia Research (25 papers), Peptidase Inhibition and Analysis (20 papers), Cancer therapeutics and mechanisms (17 papers) and Lymphoma Diagnosis and Treatment (14 papers). The work is most often cited by research in Hematology (6.5k citations), Oncology (4.4k citations), Genetics (1.3k citations), Immunology (1.8k citations) and Infectious Diseases (1.5k citations). David H. Vesole has collaborated with scholars based in United States, Canada and Poland. Frequent co-authors include Sundar Jagannath, Bart Barlogie, Guido Tricot, David S. Siegel, Morie A. Gertz, Philip R. Greipp, Joan Bladé, Sergio Giralt, B. Björkstrand and Diana Samson. Their work appears in journals such as Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact